EANS-Adhoc: Dr. Alfred Bach resigns as CEO of SYGNIS Pharma AG

@@start.t1@@--------------------------------------------------------------------------------   ad-hoc disclosure pursuant to section 15 of the WpHG transmitted by euro   adhoc with the aim of a Europe-wide distribution. The issuer is solely   responsible for the content of this announcement. --------------------------------------------------------------------------------@@end@@

C.E.O. Interviews



Dr. Alfred Bach resigns as CEO of SYGNIS Pharma AG

Heidelberg, 28 October 2010 - SYGNIS Pharma AG (Frankfurt: LIO; ISIN DE0005043509; Prime Standard) announced today that the management contract of Dr. Alfred Bach, which is going to expire at the end of the calendar-year, will not be extended upon Dr. Bach´s request. By mutual consent with the Supervisory Board Dr. Bach will resign as CEO of SYGNIS Pharma AG on the end of 28 October 2010.

The Supervisory Board thanks Dr. Bach for his commitment and efforts during the past years for SYGNIS Pharma AG. Peter Willinger, Chief Financial Officer, and, Dr. Frank Rathgeb, Chief Medical Officer, will jointly lead the Company.

For further information please contact:

|Dr. Franz-Werner Haas                              |
|VP Operations / General Counsel              |
|Tel: +49 (0) 6221-454 812                        |
|Email:         |

@@start.t2@@end of announcement                                                 euro adhoc

ots Originaltext: SYGNIS Pharma AG
Im Internet recherchierbar:

Further inquiry note:
Dr. Franz-Werner Haas                            
VP Operations / General Counsel              
Tel: +49 (0) 6221-454 812                        

Branche: Biotechnology
ISIN:      DE0005043509
WKN:        504350
Index:    CDAX, Prime All Share
Börsen:  Frankfurt / regulated dealing/prime standard
              Berlin / free trade
              Hamburg / free trade
              Stuttgart / free trade
              Düsseldorf / free trade
              Hannover / free trade
              München / free trade

Weitere Meldungen: SYGNIS AG

Das könnte Sie auch interessieren: